Near-Term Uncertainty Creates Opportunities in Managed-Care Shares

""
Securities In This Article
UnitedHealth Group Inc
(UNH)
Elevance Health Inc
(ELV)
Humana Inc
(HUM)
CVS Health Corp
(CVS)
The Cigna Group
(CI)

Near-term uncertainty is creating an opportunity for long-term investors in the managed-care organization segment. Of the six narrow-moat MCO stocks that we cover—Centene CNC, Cigna CI, CVS Health CVS, Elevance ELV, Humana HUM, and UnitedHealth UNH—five are trading in undervalued territory, and even the typically premium-priced UnitedHealth looks reasonably valued to us.

There are some near-term headwinds that the industry faces, which we think will be manageable in the long run. First, renewed Medicaid redetermination activities are probably going to cut into the Medicaid population during 2023-24, which could decelerate the industry’s top-line growth prospects somewhat. However, the MCO strongholds of employer-sponsored and individual plans look likely to act as safety nets to offset about three quarters of expected Medicaid losses, which could provide cover on the bottom line as those businesses tend to be more profitable than Medicaid plans. Also, Medicare Advantage plan growth looks set to decelerate a bit due to recent moves by the Biden administration. But this end market looks likely to lead the medical insurance market’s growth for the foreseeable future, especially as Medicare Advantage’s popularity continues to increase versus traditional Medicare due to the extra benefits that older adults can receive in the former versus the latter. Additionally, the pharmacy benefit managers are coming under regulatory scrutiny for their lack of transparency, especially in variable compensation methods; even if those methods must change we expect the PBMs to switch most clients over to fee-based arrangements. Last, election cycles can create headwinds for MCO shares, but if mixed control of the federal government continues, the MCOs will likely continue to enjoy a relatively benign policy environment, which will give them more time to expand beyond the heavily regulated medical insurance business into less regulated and potentially higher-margin businesses, such as caregiving services.

The author or authors do not own shares in any securities mentioned in this article. Find out about Morningstar’s editorial policies.

More in Stocks

About the Author

Julie Utterback, CFA

Senior Equity Analyst
More from Author

Julie Utterback, CFA, is a senior equity analyst, AM Healthcare, for Morningstar*. She focuses on medical technology and service companies. She covers managed care organizations including UnitedHealth, service providers like HCA, medical suppliers such as Baxter, and life sciences companies like Danaher. She is also the chairperson of the equity research team’s capital allocation methodology.

Before joining Morningstar in 2005, Utterback was an equity analyst at State Farm Insurance for several years. Utterback joined Morningstar in 2005 as an equity analyst in the healthcare industry, and initially she primarily covered medical technology companies, including orthopedic device, medical equipment, and cardiac device firms. In 2010, she joined Morningstar's credit research team, initiating coverage of the entire healthcare industry and generally helping the organization expand and maintain its credit coverage across many industries. She held that senior credit analyst role until April 2019, when she returned to the equity team to cover medical technology and service companies.

Utterback holds a bachelor's degree in finance from the University of Illinois Urbana-Champaign’s Gies College of Business. She also holds the Chartered Financial Analyst® designation.

* Morningstar Research Services LLC (“Morningstar”) is a wholly owned subsidiary of Morningstar, Inc

Sponsor Center